Clinical trials of an innovative drug for the treatment of depression and panic disorder have started at Sechenov University

At the First Moscow State Medical University named after I.M. Sechenov began clinical trials of a drug for the treatment of depression and panic disorder. The medicine was developed by the ChemRar group of companies, a leading domestic developer and manufacturer of innovative drugs. To create a high-tech production of active pharmaceutical substances, Sechenov University and API-Technologies LLC (part of the ChemRar Group) received a government subsidy.

Head of the Department of Psychiatry and Narcology of the First Moscow State Medical University, Corresponding Member of the Russian Academy of Sciences, Honored Doctor of the Russian Federation, Professor, Doctor of Medical Sciences Marina Kinkulkina said that the new drug affects adrenergic, dopamine , serotonin and histamine receptors, which determines its antidepressant and anti-anxiety effect.

Previously, the drug showed high efficiency and good tolerability in clinical studies and was registered by the Russian Ministry of Health for medical use in the treatment of generalized anxiety disorder and adaptation disorders, including in elderly patients. The new medicine does not cause drowsiness or withdrawal symptoms and has an antiasthenic effect.

In a clinical trial launched at Sechenov University, specialists will study the effectiveness of the drug in treating patients suffering from depression and panic disorder.

“Depression and panic disorder are widespread all over the world, including in Russia,” noted Marina Kinkulkina . – The emergence of a new domestic drug opens up new prospects for providing care to patients. We have high hopes for this drug.”

The project leader, director of the Institute of Translational Medicine and Biotechnology of the First Moscow State Medical University, Vadim Tarasov, emphasized that cooperation with the leaders of the Russian pharmaceutical industry in the development of domestic innovative medicines is one of the priorities within the development program of Sechenov University. “Over the past 5 years, we have created an advanced research base and developed competencies in drug development. The joint implementation of this project with the ChemRar group of companies serves as a good confirmation of its relevance in the industry,” the specialist concluded.